Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY - Derivative Liability for Authorized Share Deficiency (Details)

v3.21.1
STOCKHOLDERS' EQUITY - Derivative Liability for Authorized Share Deficiency (Details) - USD ($)
$ in Thousands
9 Months Ended
Mar. 31, 2021
Feb. 17, 2021
Feb. 16, 2021
Jun. 30, 2020
STOCKHOLDERS' EQUITY        
Common stock, shares authorized 10,000,000 10,000,000 500,000,000 500,000,000
Common stock, shares issued 8,352,000 8,352,000   5,867,000
Common stock, shares outstanding 8,352,000 8,352,000   5,867,000
Shares reserved for issuance   2,428,000    
Shares subject to the deficiency, required to settle in cash   780,000    
Reclassification of fair value from stockholders' equity to a liability (in shares) 740,000 780,000    
Fair value of stock options and warrants $ 1,807 $ 3,591    
Number of stock options expired 40,000,000